A scalable method for the production of high-titer and high-quality adeno-associated type 9 vectors using the HSV platform

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16031-

  Adamson Small, Laura ^a   Potter, Mark ^a   Falk, Darin J ^b   Cleaver, Brian ^a   Byrne, Barry J ^a   Clément, Nathalie ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; CAPSID PROTEIN;

ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HEK293 CELL LINE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCALE UP; VIRAL GENE DELIVERY SYSTEM; VIROGENESIS; VIRUS CAPSID; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PURIFICATION; GENETIC TRANSFECTION; LARGE SCALE PRODUCTION; MIXED INFECTION; PROMOTER REGION; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 85015200249     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.31     Document Type: Article

References (52)

1. 1 Clement, N, Grieger, J, Manufacturing of recombinant adeno-associated vectors for clinical trials. Mol Ther Methods, 3, 2016, 16002.
2. 2 Todd, AG, McElroy, JA, Grange, RW, Fuller, DD, Walter, GA, Byrne, BJ, et al. Correcting neuromuscular deficits with gene therapy in Pompe disease. Ann Neurol 78 (2015), 222–234.
3. 3 Mendell, JR, Rodino-Klapac, L, Sahenk, Z, Malik, V, Kaspar, BK, Walker, CM, et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 527 (2012), 90–99.
4. 4 Mah, CS, Soustek, MS, Todd, AG, McCall, A, Smith, BK, Corti, M, et al. Adeno-associated virus-mediated gene therapy for metabolic myopathy. Hum Gene Ther 24 (2013), 928–936.
5. 5 Ramos, J, Chamberlain, JS, Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3 (2015), 1255–1266.
6. 6 Smith, BK, Collins, SW, Conlon, TJ, Mah, CS, Lawson, LA, Martin, AD, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther 24 (2013), 630–640.
7. 7 Byrne, BJ, Smith, B, Mah, C, Lawson, LA, Islam, S, Corti, M, et al. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev 25 (2014), 134–163.
8. 8 Kornegay, JN, Spurney, CF, Nghiem, PP, Brinkmeyer-Langford, CL, Hoffman, EP, Nagaraju, K, Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J 55 (2014), 119–149.
9. 9 Mulcahy, PJ, Iremonger, K, Karyka, E, Herranz-Martín, S, Shum, KT, Tam, JK, et al. Gene therapy: a promising approach to treating spinal muscular atrophy. Hum Gene Ther 25 (2014), 575–586.
10. 10 Inagaki, K, Fuess, S, Storm, TA, Gibson, GA, Mctiernan, CF, Kay, MA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14 (2006), 45–53.
11. 11 Pacak, CA, Mah, CS, Thattaliyath, BD, Conlon, TJ, Lewis, MA, Cloutier, DE, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99 (2006), e3–e9.
12. 12 Pacak, CA, Sakai, Y, Thattaliyath, BD, Mah, CS, Byrne, BJ, Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther, 6, 2008, 13.
13. 13 Bevan, AK, Duque, S, Foust, KD, Morales, PR, Braun, L, Schmelzer, L, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19 (2011), 1971–1980.
14. 14 DeRuisseau, LR, Fuller, DD, Qiu, K, DeRuisseau, KC, Donnelly, WH Jr, Mah, C, et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci USA 106 (2009), 9419–9424.
15. 15 ElMallah, MK, Falk, DJ, Lane, MA, Conlon, TJ, Lee, KZ, Shafi, NI, et al. Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 23 (2012), 148–156.
16. 16 Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004), 828–834.
17. 17 Kornegay, JN, Li, J, Bogan, JR, Bogan, DJ, Chen, C, Zheng, H, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18 (2010), 1501–1508.
18. 18 Falk, DJ, Mah, CS, Soustek, MS, Lee, KZ, Elmallah, MK, Cloutier, DA, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 21 (2013), 1661–1667.
19. 19 Falk, DJ, Soustek, MS, Todd, AG, Mah, CS, Cloutier, DA, Kelley, JS, et al. Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther Methods Clin Dev, 2, 2015, 15007.
20. 20 Blankinship, MJ, Gregorevic, P, Chamberlain, JS, Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther 13 (2006), 241–249.
21. 21 Grieger, JC, Soltys, SM, Samulski, RJ, Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 24 (2016), 287–297.
22. 22 Grimm, D, Kern, A, Rittner, K, Kleinschmidt, JA, Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9 (1998), 2745–2760.
23. 23 Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002), 158–167.
24. 24 Clark, KR, Recent advances in recombinant adeno-associated virus vector production. Kidney Int 61:1 Suppl (2002), S9–15.
25. 25 Aslanidi, G, Lamb, K, Zolotukhin, S, An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci USA 106 (2009), 5059–5064.
26. 26 Cecchini, S, Virag, T, Kotin, RM, Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum Gene Ther 22 (2011), 1021–1030.
27. 27 Mietzsch, M, Grasse, S, Zurawski, C, Weger, S, Bennett, A, Agbandje-McKenna, M, et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 25 (2014), 212–222.
28. 28 Virag, T, Cecchini, S, Kotin, RM, Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther 20 (2009), 807–817.
29. 29 Conway, JE, Rhys, CM, Zolotukhin, I, Zolotukhin, S, Muzyczka, N, Hayward, GS, et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 6 (1999), 986–993.
30. 30 Conway, JE, Zolotukhin, S, Muzyczka, N, Hayward, GS, Byrne, BJ, Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 71 (1997), 8780–8789.
31. 31 Kang, W, Wang, L, Harrell, H, Liu, J, Thomas, DL, Mayfield, TL, et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 16 (2009), 229–239.
32. 32 Thomas, DL, Wang, L, Niamke, J, Liu, J, Kang, W, Scotti, MM, et al. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther 20 (2009), 861–870.
33. 33 Urabe, M, Ding, C, Kotin, RM, Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13 (2002), 1935–1943.
34. 34 Kohlbrenner, E, Aslanidi, G, Nash, K, Shklayev, S, Campbell-Thompson, M, Byrne, BJ, et al. Successful production of pseudotyped mosaic rAAV vectors using a modified baculovirus expression system. Molecular Therapy, 11, 2005, S155.
35. 35 Mietzsch, M, Casteleyn, V, Weger, S, Zolotukhin, S, Heilbronn, R, OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther 26 (2015), 688–697.
36. 36 Flotte, TR, Trapnell, BC, Humphries, M, Carey, B, Calcedo, R, Rouhani, F, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther 22 (2011), 1239–1247.
37. 37 Potter, M, Lins, B, Mietzsch, M, Heilbronn, R, Van Vliet, K, Chipman, P, et al. A simplified purification protocol for recombinant adeno-associated virus vectors. Mol Ther Methods Clin Dev, 1, 2014, 14034.
38. 38 Knop, DR, Harrell, H, Bioreactor production of recombinant herpes simplex virus vectors. Biotechnol Prog 23 (2007), 715–721.
39. 39 Booth, MJ, Mistry, A, Li, X, Thrasher, A, Coffin, RS, Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 11 (2004), 829–837.
40. 40 Toublanc, E, Benraiss, A, Bonnin, D, Blouin, V, Brument, N, Cartier, N, et al. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines. J Gene Med 6 (2004), 555–564.
41. 41 Clément, N, Knop, DR, Byrne, BJ, Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther 20 (2009), 796–806.
42. 42 Chulay, JD, Ye, GJ, Thomas, DL, Knop, DR, Benson, JM, Hutt, JA, et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 22 (2011), 155–165.
43. 43 Vandenberghe, LH, Xiao, R, Lock, M, Lin, J, Korn, M, Wilson, JM, Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther 21 (2010), 1251–1257.
44. 44 Smith, RH, Ding, C, Kotin, RM, Serum-free production and column purification of adeno-associated virus type 5. J Virol Methods 114 (2003), 115–124.
45. 45 Lock, M, Alvira, M, Vandenberghe, LH, Samanta, A, Toelen, J, Debyser, Z, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 21 (2010), 1259–1271.
46. 46 Rice, SA, Knipe, DM, Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. J Virol 64 (1990), 1704–1715.
47. 47 Clark, KR, Voulgaropoulou, F, Johnson, PR, A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther 3 (1996), 1124–1132.
48. 48 Klein, RL, Meyer, EM, Peel, AL, Zolotukhin, S, Meyers, C, Muzyczka, N, et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 150 (1998), 183–194.
49. 49 Zolotukhin, S, Potter, M, Hauswirth, WW, Guy, J, Muzyczka, N, A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70 (1996), 4646–4654.
50. 50 Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6 (1999), 973–985.
51. 51 Conway, JE, Herpes Simplex Virus Type I based systems for the large scale production of recombinant adeno-associated virus type 2 vectors. College of Medicine, vol. Ph.D., 2001, Johns Hopkins University, 184.
52. 52 Falk, DJ, Mah, CS, Soustek, MS, Lee, KZ, Elmallah, MK, Cloutier, DA, et al. Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther 21 (2013), 1661–1667.